{
    "nctId": "NCT01088477",
    "briefTitle": "Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer",
    "officialTitle": "Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 21,
    "primaryOutcomeMeasure": "Quantifying FES-uptake to predict response to estrogen therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with the diagnosis of acquired anti-hormonal resistant advanced breast cancer showing progression after two or more lines of antihormonal treatment;\n2. Treatment with estradiol will be started;\n3. Age\\> 18 years;\n4. ECOG performance status 0-2.\n\nExclusion Criteria:\n\n1. Life Expectancy \\<3 months;\n2. Uncontrolled CNS metastases;\n3. History of thrombosis;\n4. Uncontrolled hypercalcemia;\n5. Treatment with any investigational drug within 30 days before start of study;\n6. Serious uncontrolled concurrent illness, e.g. autoimmune disorders;\n7. New York Hearth Association (NYHA) class III/IV congestive heart failure;\n8. Dyspnea at rest due to any cause;\n9. Pregnant or lactating women. Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause;\n10. Women of childbearing potential unless a) surgically sterile or b) using adequate measures of contraception.\n11. Diabetes Mellitus",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}